We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Migranal

News List

Cipla Receives Final Approval for Generic Version Migranal americanpharmaceuticalreview
May 26, 2020
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (FDA) with a Competitive Generic Therapy (CGT) designation.
Cipla receives final approval for generic version of Migranal with a Competitive Generic Therapy Des expresspharma
May 21, 2020
Cipla is the “first approved applicant” for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product.